Published in J Exp Med on December 22, 2008
The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction. J Mol Cell Cardiol (2009) 2.80
Matricellular proteins in cardiac adaptation and disease. Physiol Rev (2012) 2.01
The pathogenesis of cardiac fibrosis. Cell Mol Life Sci (2013) 1.96
Matrix metalloproteinase-28 deletion exacerbates cardiac dysfunction and rupture after myocardial infarction in mice by inhibiting M2 macrophage activation. Circ Res (2012) 1.94
The role of SPARC in extracellular matrix assembly. J Cell Commun Signal (2009) 1.43
Age-dependent alterations in fibrillar collagen content and myocardial diastolic function: role of SPARC in post-synthetic procollagen processing. Am J Physiol Heart Circ Physiol (2009) 1.41
Proteomic analysis of Sox2-associated proteins during early stages of mouse embryonic stem cell differentiation identifies Sox21 as a novel regulator of stem cell fate. Stem Cells (2010) 1.40
Extracellular matrix roles during cardiac repair. Life Sci (2010) 1.32
Extracellular matrix turnover and signaling during cardiac remodeling following MI: causes and consequences. J Mol Cell Cardiol (2009) 1.31
The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis. Circ Res (2016) 1.27
Cardiac extracellular matrix remodeling: fibrillar collagens and Secreted Protein Acidic and Rich in Cysteine (SPARC). J Mol Cell Cardiol (2009) 1.27
SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice. Gut (2013) 1.21
Cellular mechanisms of tissue fibrosis. 2. Contributory pathways leading to myocardial fibrosis: moving beyond collagen expression. Am J Physiol Cell Physiol (2012) 1.21
Differential gene expression in granulosa cells from polycystic ovary syndrome patients with and without insulin resistance: identification of susceptibility gene sets through network analysis. J Clin Endocrinol Metab (2012) 1.14
SPARC: a key player in the pathologies associated with obesity and diabetes. Nat Rev Endocrinol (2010) 1.11
Quantitative N-linked glycoproteomics of myocardial ischemia and reperfusion injury reveals early remodeling in the extracellular environment. Mol Cell Proteomics (2011) 1.09
The immune system and the remodeling infarcted heart: cell biological insights and therapeutic opportunities. J Cardiovasc Pharmacol (2014) 1.08
Systematic characterization of myocardial inflammation, repair, and remodeling in a mouse model of reperfused myocardial infarction. J Histochem Cytochem (2013) 1.06
Function and fate of myofibroblasts after myocardial infarction. Fibrogenesis Tissue Repair (2013) 1.05
The extracellular matrix modulates fibroblast phenotype and function in the infarcted myocardium. J Cardiovasc Transl Res (2012) 1.01
SPARC regulates collagen interaction with cardiac fibroblast cell surfaces. Am J Physiol Heart Circ Physiol (2011) 1.00
Integrating the myocardial matrix into heart failure recognition and management. Circ Res (2013) 1.00
SPARC oppositely regulates inflammation and fibrosis in bleomycin-induced lung damage. Am J Pathol (2011) 0.94
Thrombospondins in the heart: potential functions in cardiac remodeling. J Cell Commun Signal (2009) 0.93
Extracellular matrix and fibroblast communication following myocardial infarction. J Cardiovasc Transl Res (2012) 0.93
SPARC deficiency results in improved surgical survival in a novel mouse model of glaucoma filtration surgery. PLoS One (2010) 0.92
Collagen extracts derived from young and aged mice demonstrate different structural properties and cellular effects in three-dimensional gels. J Gerontol A Biol Sci Med Sci (2010) 0.91
Aging and the cardiac collagen matrix: Novel mediators of fibrotic remodelling. J Mol Cell Cardiol (2015) 0.91
SPARC mediates early extracellular matrix remodeling following myocardial infarction. Am J Physiol Heart Circ Physiol (2011) 0.90
Cardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failure. Cardiovasc Res (2010) 0.88
Role of matricellular proteins in cardiac tissue remodeling after myocardial infarction. World J Biol Chem (2010) 0.88
Proteins involved in platelet signaling are differentially regulated in acute coronary syndrome: a proteomic study. PLoS One (2010) 0.87
Secreted protein acidic and rich in cysteine is a matrix scavenger chaperone. PLoS One (2011) 0.87
Loss of fibulin-2 protects against progressive ventricular dysfunction after myocardial infarction. J Mol Cell Cardiol (2011) 0.86
Matrix metalloproteinases: drug targets for myocardial infarction. Curr Drug Targets (2013) 0.84
Conditioned medium from human amniotic mesenchymal stromal cells limits infarct size and enhances angiogenesis. Stem Cells Transl Med (2015) 0.83
Using proteomics to uncover extracellular matrix interactions during cardiac remodeling. Proteomics Clin Appl (2013) 0.83
Targeting the chemokines in cardiac repair. Curr Pharm Des (2014) 0.82
SPARC is expressed in scars of the Tenon's capsule and mediates scarring properties of human Tenon's fibroblasts in vitro. Mol Vis (2011) 0.80
SPARC-Dependent Cardiomyopathy in Drosophila. Circ Cardiovasc Genet (2016) 0.79
Gene Expression Profiles Link Respiratory Viral Infection, Platelet Response to Aspirin, and Acute Myocardial Infarction. PLoS One (2015) 0.78
Temporal cardiac remodeling post-myocardial infarction: dynamics and prognostic implications in personalized medicine. Heart Fail Rev (2015) 0.78
Extracellular matrix-mediated cellular communication in the heart. J Mol Cell Cardiol (2016) 0.78
Physiological Implications of Myocardial Scar Structure. Compr Physiol (2015) 0.78
The extracellular matrix in myocardial injury, repair, and remodeling. J Clin Invest (2017) 0.77
Follistatin-like 1 promotes cardiac fibroblast activation and protects the heart from rupture. EMBO Mol Med (2016) 0.77
Influence of vascular endothelial growth factor stimulation and serum deprivation on gene activation patterns of human adipose tissue-derived stromal cells. Stem Cell Res Ther (2015) 0.77
Tracheal Aspirate Levels of the Matricellular Protein SPARC Predict Development of Bronchopulmonary Dysplasia. PLoS One (2015) 0.76
SPARC/osteonectin in mineralized tissue. Matrix Biol (2016) 0.76
Changes in the myocardial interstitium and contribution to the progression of heart failure. Heart Fail Clin (2012) 0.76
Mechanical regulation of cardiac fibroblast pro-fibrotic phenotypes. Mol Biol Cell (2017) 0.75
Fibroblast-Extracellular Matrix Interactions in Tissue Fibrosis. Curr Pathobiol Rep (2016) 0.75
SPARCling Study of a Drosophila Cardiomyopathy. Circ Cardiovasc Genet (2016) 0.75
Endogenous migration modulators as parent compounds for the development of novel cardiovascular and anti-inflammatory drugs. Br J Pharmacol (2012) 0.75
Comparison of multiple single-nucleotide variant association tests in a meta-analysis of Genetic Analysis Workshop 19 family and unrelated data. BMC Proc (2016) 0.75
Breeding Strategy Determines Rupture Incidence in Post-Infarct Healing WARPing Cardiovascular Research. PLoS One (2015) 0.75
A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A (1998) 24.58
A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet (2003) 12.16
Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem J (1979) 8.95
Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med (1999) 4.85
The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res (2006) 4.38
SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest (2001) 3.13
SPARC and tumor growth: where the seed meets the soil? J Cell Biochem (2004) 2.75
Polymerization of type I and III collagens is dependent on fibronectin and enhanced by integrins alpha 11beta 1 and alpha 2beta 1. J Biol Chem (2002) 2.26
Critical role of endogenous thrombospondin-1 in preventing expansion of healing myocardial infarcts. Circulation (2005) 2.09
Postinfarction gene therapy against transforming growth factor-beta signal modulates infarct tissue dynamics and attenuates left ventricular remodeling and heart failure. Circulation (2005) 1.90
SPARC regulates extracellular matrix organization through its modulation of integrin-linked kinase activity. J Biol Chem (2005) 1.70
SPARC regulates processing of procollagen I and collagen fibrillogenesis in dermal fibroblasts. J Biol Chem (2007) 1.68
SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system. Mol Biol Cell (2003) 1.63
Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. Circ Res (2001) 1.56
Imatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2)27 rats. Hypertension (2006) 1.53
Mouse model of post-infarct ventricular rupture: time course, strain- and gender-dependency, tensile strength, and histopathology. Cardiovasc Res (2005) 1.52
Matricellular proteins in the heart: possible role during stress and remodeling. Cardiovasc Res (2004) 1.51
Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. Cardiovasc Res (2004) 1.49
SPARC-null mice exhibit accelerated cutaneous wound closure. J Histochem Cytochem (2002) 1.47
Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury. Am J Pathol (2005) 1.46
Extracellular matrix remodeling following myocardial injury. Ann Med (2003) 1.41
Estrogen and testosterone have opposing effects on chronic cardiac remodeling and function in mice with myocardial infarction. Am J Physiol Heart Circ Physiol (2003) 1.37
Extracellular matrix remodeling in canine and mouse myocardial infarcts. Cell Tissue Res (2006) 1.36
Characterization of SMOC-2, a modular extracellular calcium-binding protein. Biochem J (2003) 1.31
SPARC regulates TGF-beta1-dependent signaling in primary glomerular mesangial cells. J Cell Biochem (2004) 1.24
Characterization of SMOC-1, a novel modular calcium-binding protein in basement membranes. J Biol Chem (2002) 1.23
Increased expression of syndecan-1 protects against cardiac dilatation and dysfunction after myocardial infarction. Circulation (2007) 1.13
Matricellular hevin regulates decorin production and collagen assembly. J Biol Chem (2006) 1.09
Testosterone enhances early cardiac remodeling after myocardial infarction, causing rupture and degrading cardiac function. Am J Physiol Heart Circ Physiol (2005) 1.06
Compromised production of extracellular matrix in mice lacking secreted protein, acidic and rich in cysteine (SPARC) leads to a reduced foreign body reaction to implanted biomaterials. Am J Pathol (2003) 1.04
Impaired wound healing in mice deficient in a matricellular protein SPARC (osteonectin, BM-40). BMC Cell Biol (2001) 1.00
Cloning and expression of murine SC1, a gene product homologous to SPARC. J Histochem Cytochem (1997) 1.00
Structural variability of BM-40/SPARC/osteonectin glycosylation: implications for collagen affinity. Glycobiology (2004) 0.93
Spatially and temporally different expression of osteonectin and osteopontin in the infarct zone of experimentally induced myocardial infarction in rats. Cardiovasc Pathol (2003) 0.87
Purification of SPARC/osteonectin. Curr Protoc Cell Biol (2003) 0.82
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med (2013) 11.14
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 9.70
Hypoxia and inflammation. N Engl J Med (2011) 7.71
Gene prioritization through genomic data fusion. Nat Biotechnol (2006) 7.48
Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet (2006) 7.33
A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA (2004) 7.32
Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med (2005) 6.86
Basic and therapeutic aspects of angiogenesis. Cell (2011) 6.40
uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol (2002) 6.24
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med (2013) 6.01
Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med (2002) 5.50
Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med (2002) 5.10
Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell (2007) 5.09
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet (2002) 5.04
Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol (2002) 4.23
VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet (2003) 4.19
Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res (2012) 4.06
Modification of kidney barrier function by the urokinase receptor. Nat Med (2007) 4.01
miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res (2008) 3.96
Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet (2008) 3.94
HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell (2011) 3.89
The European dimension for the mouse genome mutagenesis program. Nat Genet (2004) 3.84
MiR423-5p as a circulating biomarker for heart failure. Circ Res (2010) 3.83
The netrin receptor UNC5B mediates guidance events controlling morphogenesis of the vascular system. Nature (2004) 3.77
Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet (2010) 3.75
Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest (2002) 3.70
The second Euro Heart Survey on acute coronary syndromes: Characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. Eur Heart J (2006) 3.62
Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J (2013) 3.50
A Sertoli cell-selective knockout of the androgen receptor causes spermatogenic arrest in meiosis. Proc Natl Acad Sci U S A (2004) 3.48
Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA (2007) 3.48
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer (2008) 3.46
VE-Cadherin-Cre-recombinase transgenic mouse: a tool for lineage analysis and gene deletion in endothelial cells. Dev Dyn (2006) 3.38
Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci (2004) 3.31
Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell (2009) 3.27
A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature (2011) 3.25
Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. J Am Coll Cardiol (2008) 3.24
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med (2011) 3.20
Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med (2003) 3.17
Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell (2002) 3.11
VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature (2004) 3.08
Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation (2004) 3.05
Role of PFKFB3-driven glycolysis in vessel sprouting. Cell (2013) 3.04
Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell (2011) 3.00
Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. Circulation (2008) 2.95
NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J (2005) 2.93
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol (2012) 2.92
Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J Cell Biol (2008) 2.91
VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays (2004) 2.83
Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? J Mol Med (Berl) (2004) 2.81
SPARC and tumor growth: where the seed meets the soil? J Cell Biochem (2004) 2.75
Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med (2006) 2.75
Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J (2002) 2.74
Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell (2013) 2.64
Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J Am Coll Cardiol (2010) 2.50
Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med (2009) 2.49
International differences in evolution of early discharge after acute myocardial infarction. Lancet (2004) 2.47
Increased adipose tissue oxygen tension in obese compared with lean men is accompanied by insulin resistance, impaired adipose tissue capillarization, and inflammation. Circulation (2011) 2.41
Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Mech Dev (2002) 2.39
CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res (2005) 2.38
VEGF receptor 2 endocytic trafficking regulates arterial morphogenesis. Dev Cell (2010) 2.37
Protective role of reactive astrocytes in brain ischemia. J Cereb Blood Flow Metab (2007) 2.35
Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy. Circ Res (2004) 2.31
Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol (2006) 2.29
Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circ Res (2004) 2.29
Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. J Am Coll Cardiol (2012) 2.28
Impact of myocardial haemorrhage on left ventricular function and remodelling in patients with reperfused acute myocardial infarction. Eur Heart J (2009) 2.27
Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell (2010) 2.26
Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA (2005) 2.26
Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol (2013) 2.22
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J (2011) 2.21
Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci (2003) 2.20
VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J (2006) 2.20
Sex differences in mortality following acute coronary syndromes. JAMA (2009) 2.17
Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go. Eur Heart J (2008) 2.16
Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and combined management from the perspective of atrial fibrillation: results of the Euro Heart Survey on atrial fibrillation. J Am Coll Cardiol (2009) 2.16
Primary prevention of sudden death in patients with lamin A/C gene mutations. N Engl J Med (2006) 2.16
Reversible isolated left ventricular non-compaction? Int J Cardiol (2008) 2.15
Neurovascular signalling defects in neurodegeneration. Nat Rev Neurosci (2008) 2.15
External validity of clinical trials in acute myocardial infarction. Arch Intern Med (2007) 2.14
Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet (2009) 2.13
Avoidance of transient cardiomyopathy in cardiomyocyte-targeted tamoxifen-induced MerCreMer gene deletion models. Circ Res (2009) 2.11
Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat Rev Drug Discov (2009) 2.10
The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events. Am J Med (2002) 2.09
The FGF system has a key role in regulating vascular integrity. J Clin Invest (2008) 2.09
Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res (2003) 2.08
Regulation of angiogenesis by oxygen and metabolism. Dev Cell (2009) 2.04
Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest (2013) 2.03
Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6. Blood (2009) 2.01